Research Grade Anti-SARS-CoV-2 RBD antibody (H4) (VK565083)

Datasheet Share product Copy info

Price(USD): $

Spec:

20ug
50ug
100ug
1mg

Number:

Overview
Images
References
Datasheet

Overview

Catalog No.

VK565083

Description

Anti-SARS-CoV-2 RBD antibody (H4) (VK565083) is a research-grade recombinant antibody targeting Spike glycoprotein. Produced in mammalian cells with native-like glycosylation.

Highlights

●Research Grade — For PK/PD studies, assay development, and ADA research.
●Native Glycosylation — Mammalian expression ensures native-like patterns.

Species reactivity

SARS-CoV-2 (2019-nCoV)

Applications

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Host species

Human

Isotype

IgG1

Clone ID

Expression system

Mammalian Cells

Clonality

Monoclonal

Target

Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2

Endotoxin level

Please contact the lab for this information.

Purity

>95% purity as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P0DTC2

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:2000-1:20000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

Background

Spike glycoprotein (RBD) is a ~141 kDa protein. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2. When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane. When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis using host TFRC and GRM2 and leading to fusion of the virion membrane with the host endosomal membrane. Alternatively, may use NRP1/NRP2 and integrin as entry receptors.

1. Hoffmann, M. et al. (2020) Cell 181, 271-280.e8. PMID: 32142651

2. Walls, AC. et al. (2020) Cell 181, 281-292.e6. PMID: 32155444

3. Cao, W. et al. (2021) Biophysical journal 120, 1011-1019. PMID: 33607086

4. Takeda, M. (2022) Microbiology and immunology 66, 15-23. PMID: 34561887

5. Wrapp, D. et al. (2020) Science (New York, N.Y.) 367, 1260-1263. PMID: 32075877

6. Ou, X. et al. (2020) Nature communications 11, 1620. PMID: 32221306

7. Wang, J. et al. (2021) Cell discovery 7, 119. PMID: 34903715

8. Wang, X. et al. (2023) Journal of virology 97, e0161122. PMID: 36779763

9. Daly, JL. et al. (2020) Science (New York, N.Y.) 370, 861-865. PMID: 33082294

10. Cantuti-Castelvetri, L. et al. (2020) Science (New York, N.Y.) 370, 856-860. PMID: 33082293

Note

For research use only. Not suitable for clinical or therapeutic use.

Images

Bioactivity

Detects Recombinant SARS-CoV-2 Spike protein receptor binding domain (Cat No.: VK565021) in indirect ELISA.
SDS-PAGE

SDS-PAGE for Research Grade Anti-SARS-CoV-2 RBD antibody (H4)